Journal
BONE MARROW TRANSPLANTATION
Volume 54, Issue -, Pages 780-784Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41409-019-0602-5
Keywords
-
Categories
Funding
- Bezos Family Foundation
- Gilead Sciences Europe Ltd
- Cell Source, Inc.
- Chorafas Institute for Scientific Exchange of the Weizmann Institute of Science
- Kiadis Pharma
- Miltenyi Biotec
- Celgene
- Centro Servizi Congressuali
- Almog Diagnostic
Ask authors/readers for more resources
Adoptive immunotherapy with CD19-targeted chimeric antigen receptor (CAR)-T cells has been successful in producing durable remissions in some patients with relapsed or refractory B cell malignancies. Despite the efficacy of CAR-T cell therapy, significant toxicities can occur. Cytokine release syndrome (CRS) and neurotoxicity are the most common toxicities and can range from self-limited fever to life threatening organ damage and death. Understanding the mechanisms underlying these toxicities can help guide and improve outcomes. In this review we describe CRS and neurotoxicity in patients with B cell malignancies treated with CD19 CAR-T cells in pivotal trials, and also provide insight into potential mechanisms associated with these toxicities based on studies conducted in a phase 1/2 clinical trial at the Fred Hutchinson Cancer Research Center.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available